The commercial-stage biopharmaceutical company said Dr Mac Burnham’s team will explore efficacy of Avicanna’s drug candidates and its proprietary combination of cannabinoids in a pre-clinical model for seizures
Avicanna Inc (TSX:AVCN, OTCQX:AVCNF) announced that it has expanded its research collaboration in field of epilepsy through a new partnership with the University of Toronto and Dr Mac Burnham’s research team to explore the efficacy of Avicanna’s proprietary formulations in pre-clinical models for treating the disease.
The commercial-stage biopharmaceutical company said Dr Mac Burnham’s team will explore efficacy of Avicanna’s drug candidates and its proprietary combination of cannabinoids, including AVCN319302, in a pre-clinical model for seizures.
“The combination of real-world evidence and ongoing research collaborations enable us to further develop our pharmaceutical pipeline and further progress our drug candidate in the field of epilepsy,” Avicanna’s vice president of scientific and medical affairs Dr Karolina Urban said in a statement.
Avicanna noted the research collaboration will also evaluate the anti-seizure properties of rare cannabinoids in isolation, and in combination, and will be supported by the company’s current medical cannabis sales.
Dr Burnham is a professor emeritus of pharmacology and toxicology at the University of Toronto’s Temerty Faculty of Medicine, and with his more than 150 publications has contributed greatly to the advancement of anti-seizure therapies, according to the company.
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments.
The company has an established scientific platform including R&D and clinical development that has led to the commercialization of more than 30 products across various market segments.
Source: proactiveinvestors.com, Sean Mason
